speb/financial-data huggingface dataset:
GSK balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 14157000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Total Debt: 18432000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 13654000000.00
GSK income_statement (quarterly, 2025-03-31) — Total Expenses: 5300000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 47051000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 42620000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 26220000000.00
GSK income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 2216000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 628000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 31000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 230907190.00
GSK balance_sheet (quarterly, 2025-03-31) — Working Capital: -2746000000.00
GSK income_statement (quarterly, 2025-06-30) — +Operating Expense: 3798000000.00
GSK income_statement (quarterly, 2025-06-30) — +Total Revenue: 7986000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 14820000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 7321000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 3486000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Assets Held For Sale Current: 85000000.00
GSK income_statement (quarterly, 2025-06-30) — Basic Average Shares: 2031500000.00
GSK income_statement (quarterly, 2025-06-30) — Basic EPS: 0.71
GSK cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 4251000000.00
GSK cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -633000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Capital Stock: 1349000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 3599000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 3619000000.00
GSK cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -656000000.00
GSK cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -1031000000.00
GSK cash_flow (quarterly, 2025-06-30) — Changes In Cash: -901000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Common Stock: 1349000000.00
GSK cash_flow (quarterly, 2025-06-30) — Common Stock Dividend Paid: -656000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 14791000000.00
GSK cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 2000000.00
GSK cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -561000000.00
GSK income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2165000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Current Assets: 17673000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 2050000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 20378000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Current Provisions: 1693000000.00
GSK cash_flow (quarterly, 2025-06-30) — Deferred Tax: 241000000.00
GSK cash_flow (quarterly, 2025-06-30) — Depreciation: 1159000000.00
GSK cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 1159000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Derivative Product Liabilities: 68000000.00
GSK income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 2055000000.00
GSK income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.70
GSK income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 1443000000.00
GSK cash_flow (quarterly, 2025-06-30) — Dividends Received Cfi: 0.00
GSK income_statement (quarterly, 2025-06-30) — EBIT: 2071000000.00
GSK income_statement (quarterly, 2025-06-30) — EBITDA: 3230000000.00
GSK cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -26000000.00
GSK cash_flow (quarterly, 2025-06-30) — End Cash Position: 3324000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Financial Assets: 0.00
GSK cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -2372000000.00
GSK cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 1463000000.00
GSK income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 2140000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Goodwill: 6734000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 22110000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Gross PPE: 9918000000.00
GSK income_statement (quarterly, 2025-06-30) — Gross Profit: 5821000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Hedging Assets Current: 200000000.00
GSK income_statement (quarterly, 2025-06-30) — Interest Expense: 184000000.00
GSK income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 184000000.00
GSK income_statement (quarterly, 2025-06-30) — Interest Income: 50000000.00
GSK income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 50000000.00
GSK cash_flow (quarterly, 2025-06-30) — Interest Paid Cff: -256000000.00
GSK cash_flow (quarterly, 2025-06-30) — Interest Received Cfi: 39000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Inventory: 6072000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Invested Capital: 14791000000.00
GSK cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -625000000.00
GSK cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 2000000.00
GSK cash_flow (quarterly, 2025-06-30) — Issuance Of Debt: 645000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 15304000000.00
GSK cash_flow (quarterly, 2025-06-30) — Long Term Debt Issuance: -35000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Long Term Equity Investment: 88000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Long Term Provisions: 575000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Minority Interest: -437000000.00
GSK income_statement (quarterly, 2025-06-30) — Minority Interests: -203000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: -36000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -559000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Income: 1443000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 1443000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 1646000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 1443000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 1443000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 1646000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 1646000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -377000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Interest Income: -134000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 0.00
GSK cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -874000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -1444000000.00
GSK income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -134000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 148000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Net PPE: 9918000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -251000000.00
GSK cash_flow (quarterly, 2025-06-30) — Net Short Term Debt Issuance: 570000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -7319000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 6581000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 384000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Non Current Pension And Other Postretirement Benefit Plans: 1752000000.00
GSK income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 3230000000.00
GSK income_statement (quarterly, 2025-06-30) — Normalized Income: 1443000000.00
GSK cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 2096000000.00
GSK income_statement (quarterly, 2025-06-30) — Operating Income: 2023000000.00
GSK income_statement (quarterly, 2025-06-30) — Operating Revenue: 7986000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 4046397628.00
GSK balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 1134000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 15376000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Other Investments: 889000000.00
GSK cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 134000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 1999000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 6442000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Other Properties: 9918000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 20000000.00
GSK income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (quarterly, 2025-06-30) — Payables: 15401000000.00
GSK income_statement (quarterly, 2025-06-30) — Pretax Income: 1887000000.00
GSK cash_flow (quarterly, 2025-06-30) — Purchase Of Business: -54000000.00
GSK cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -377000000.00
GSK cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -256000000.00
GSK income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2165000000.00
GSK income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 1159000000.00
GSK cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -1519000000.00
GSK cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -561000000.00
GSK income_statement (quarterly, 2025-06-30) — Research And Development: 2024000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 8797000000.00
GSK cash_flow (quarterly, 2025-06-30) — Sale Of Business: 18000000.00
GSK cash_flow (quarterly, 2025-06-30) — Sale Of Intangibles: 0.00
GSK cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 5000000.00
GSK income_statement (quarterly, 2025-06-30) — Selling General And Administration: 2140000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Share Issued: 4315370199.00
GSK cash_flow (quarterly, 2025-06-30) — Short Term Debt Issuance: 680000000.00
GSK cash_flow (quarterly, 2025-06-30) — Short Term Debt Payments: -110000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 14791000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -7319000000.00
GSK income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
GSK income_statement (quarterly, 2025-06-30) — Tax Provision: 241000000.00
GSK income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.13
GSK balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 376000000.00
GSK cash_flow (quarterly, 2025-06-30) — Taxes Refund Paid: -337000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Assets: 59258000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 14791000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Debt: 17354000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 14354000000.00
GSK income_statement (quarterly, 2025-06-30) — Total Expenses: 5963000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 44904000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 41585000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 24526000000.00
GSK income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 2023000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 581000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Tradeand Other Payables Non Current: 1000000.00
GSK balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 268972571.00
GSK balance_sheet (quarterly, 2025-06-30) — Working Capital: -2705000000.00
GSK income_statement (quarterly, 2025-09-30) — +Operating Expense: 3696000000.00
GSK income_statement (quarterly, 2025-09-30) — +Total Revenue: 8547000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 15675000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 7937000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 3486000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 7000000.00
GSK income_statement (quarterly, 2025-09-30) — Basic Average Shares: 2017000000.00
GSK income_statement (quarterly, 2025-09-30) — Basic EPS: 1.00
GSK cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 3324000000.00
GSK cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -879000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Capital Stock: 1349000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 3296000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 3306000000.00
GSK cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -650000000.00
GSK cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -206000000.00
GSK cash_flow (quarterly, 2025-09-30) — Changes In Cash: -624000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Common Stock: 1349000000.00
GSK cash_flow (quarterly, 2025-09-30) — Common Stock Dividend Paid: -650000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 16148000000.00
GSK cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
GSK cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -317000000.00
GSK income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 2258000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Current Assets: 17842000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 2856000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 21334000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Current Provisions: 1130000000.00
GSK cash_flow (quarterly, 2025-09-30) — Deferred Tax: 312000000.00
GSK cash_flow (quarterly, 2025-09-30) — Depreciation: 738000000.00
GSK cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 738000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Derivative Product Liabilities: 66000000.00
GSK income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 2051000000.00
GSK income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.98
GSK income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 2013000000.00
GSK cash_flow (quarterly, 2025-09-30) — Dividends Received Cfi: 17000000.00
GSK income_statement (quarterly, 2025-09-30) — EBIT: 2623000000.00
GSK income_statement (quarterly, 2025-09-30) — EBITDA: 3361000000.00
GSK cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 59000000.00
GSK cash_flow (quarterly, 2025-09-30) — End Cash Position: 2759000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Financial Assets: 0.00
GSK cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -1315000000.00
GSK cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 1343000000.00
GSK income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 2239000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Goodwill: 7117000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 23982000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Gross PPE: 10132000000.00
GSK income_statement (quarterly, 2025-09-30) — Gross Profit: 6289000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Hedging Assets Current: 107000000.00
GSK income_statement (quarterly, 2025-09-30) — Interest Expense: 167000000.00
GSK income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 167000000.00
GSK income_statement (quarterly, 2025-09-30) — Interest Income: 26000000.00
GSK income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 26000000.00
GSK cash_flow (quarterly, 2025-09-30) — Interest Paid Cff: -59000000.00
GSK cash_flow (quarterly, 2025-09-30) — Interest Received Cfi: 25000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Inventory: 6118000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Invested Capital: 16148000000.00
GSK cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1531000000.00
GSK cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
GSK cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: -80000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 14894000000.00
GSK cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: -4000000.00
GSK cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 7000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 129000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 673000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Minority Interest: -396000000.00
GSK income_statement (quarterly, 2025-09-30) — Minority Interests: -131000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: -746000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -317000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Income: 2013000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 2013000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 2144000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 2013000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 2013000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 2144000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 2144000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -532000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Interest Income: -141000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 11000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -86000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 3000000.00
GSK income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -141000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -48000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Net PPE: 10132000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -306000000.00
GSK cash_flow (quarterly, 2025-09-30) — Net Short Term Debt Issuance: -89000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -7834000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 6168000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 390000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Non Current Pension And Other Postretirement Benefit Plans: 1663000000.00
GSK income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 3361000000.00
GSK income_statement (quarterly, 2025-09-30) — Normalized Income: 2013000000.00
GSK cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 2222000000.00
GSK income_statement (quarterly, 2025-09-30) — Operating Income: 2593000000.00
GSK income_statement (quarterly, 2025-09-30) — Operating Revenue: 8547000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 4026337496.00
GSK balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 1236000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 16865000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Other Investments: 954000000.00
GSK cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 141000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 2132000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 6567000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Other Properties: 10132000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 10000000.00
GSK income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (quarterly, 2025-09-30) — Payables: 15999000000.00
GSK income_statement (quarterly, 2025-09-30) — Pretax Income: 2456000000.00
GSK cash_flow (quarterly, 2025-09-30) — Purchase Of Business: -866000000.00
GSK cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -568000000.00
GSK cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -311000000.00
GSK income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 2258000000.00
GSK income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 738000000.00
GSK cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -6000000.00
GSK cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -317000000.00
GSK income_statement (quarterly, 2025-09-30) — Research And Development: 1689000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 10016000000.00
GSK cash_flow (quarterly, 2025-09-30) — Sale Of Business: 120000000.00
GSK cash_flow (quarterly, 2025-09-30) — Sale Of Intangibles: 36000000.00
GSK cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 5000000.00
GSK income_statement (quarterly, 2025-09-30) — Selling General And Administration: 2239000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Share Issued: 4315407340.00
GSK cash_flow (quarterly, 2025-09-30) — Short Term Debt Issuance: -76000000.00
GSK cash_flow (quarterly, 2025-09-30) — Short Term Debt Payments: -13000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 16148000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -7834000000.00
GSK income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
GSK income_statement (quarterly, 2025-09-30) — Tax Provision: 312000000.00
GSK income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.13
GSK balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 367000000.00
GSK cash_flow (quarterly, 2025-09-30) — Taxes Refund Paid: -298000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Assets: 61339000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 16148000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Debt: 17750000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 15752000000.00
GSK income_statement (quarterly, 2025-09-30) — Total Expenses: 5954000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 45587000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 43497000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 24253000000.00
GSK income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 2593000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 324000000.00
GSK balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 289069844.00
GSK balance_sheet (quarterly, 2025-09-30) — Working Capital: -3492000000.00
GSK income_statement (annual, 2025-12-31) — +Operating Expense: 15312000000.00
GSK income_statement (quarterly, 2025-12-31) — +Operating Expense: 4455000000.00
GSK income_statement (annual, 2025-12-31) — +Total Revenue: 32667000000.00
GSK income_statement (quarterly, 2025-12-31) — +Total Revenue: 8618000000.00
GSK balance_sheet (annual, 2025-12-31) — Accounts Payable: 3535000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 3535000000.00
GSK balance_sheet (annual, 2025-12-31) — Accounts Receivable: 5913000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 5913000000.00
GSK balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -10892000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -10892000000.00
GSK balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 3498000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 3498000000.00
GSK cash_flow (annual, 2025-12-31) — Amortization Cash Flow: 1258000000.00
GSK balance_sheet (annual, 2025-12-31) — Assets Held For Sale Current: 300000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Assets Held For Sale Current: 300000000.00
GSK balance_sheet (annual, 2025-12-31) — Available For Sale Securities: 790000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Available For Sale Securities: 790000000.00
GSK income_statement (annual, 2025-12-31) — Basic Average Shares: 2025500000.00
GSK income_statement (quarterly, 2025-12-31) — Basic Average Shares: 2009500000.00
GSK income_statement (annual, 2025-12-31) — Basic EPS: 2.82
GSK income_statement (quarterly, 2025-12-31) — Basic EPS: 0.32
GSK cash_flow (annual, 2025-12-31) — Beginning Cash Position: 3403000000.00
GSK cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 2759000000.00
GSK balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 531000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 531000000.00
GSK cash_flow (annual, 2025-12-31) — Capital Expenditure: -2985000000.00
GSK cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -1025000000.00
GSK balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 830000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 830000000.00
GSK balance_sheet (annual, 2025-12-31) — Capital Stock: 1349000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Capital Stock: 1349000000.00
GSK balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 3150000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 3150000000.00
GSK balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 3159000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 3159000000.00
GSK cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -2564000000.00
GSK cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: -646000000.00
GSK cash_flow (annual, 2025-12-31) — Change In Inventory: -140000000.00
GSK cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -1139000000.00
GSK cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: 465000000.00
GSK cash_flow (annual, 2025-12-31) — Change In Payable: 474000000.00
GSK cash_flow (annual, 2025-12-31) — Change In Receivables: -1097000000.00
GSK cash_flow (annual, 2025-12-31) — Change In Working Capital: -1437000000.00
GSK cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 588000000.00
GSK cash_flow (annual, 2025-12-31) — Changes In Cash: -177000000.00
GSK cash_flow (quarterly, 2025-12-31) — Changes In Cash: 489000000.00
GSK balance_sheet (annual, 2025-12-31) — Common Stock: 1349000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Common Stock: 1349000000.00
GSK cash_flow (annual, 2025-12-31) — Common Stock Dividend Paid: -2564000000.00
GSK cash_flow (quarterly, 2025-12-31) — Common Stock Dividend Paid: -646000000.00
GSK balance_sheet (annual, 2025-12-31) — Common Stock Equity: 16377000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 16377000000.00
GSK cash_flow (annual, 2025-12-31) — Common Stock Issuance: 15000000.00
GSK cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 1000000.00
GSK cash_flow (annual, 2025-12-31) — Common Stock Payments: -1377000000.00
GSK cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -252000000.00
GSK balance_sheet (annual, 2025-12-31) — Construction In Progress: 2511000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 2511000000.00
GSK income_statement (annual, 2025-12-31) — Cost Of Revenue: 9017000000.00
GSK income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2657000000.00
GSK balance_sheet (annual, 2025-12-31) — Current Assets: 17510000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Current Assets: 17510000000.00
GSK balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 137000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 137000000.00
GSK balance_sheet (annual, 2025-12-31) — Current Debt: 2875000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Current Debt: 2875000000.00
GSK balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 3012000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 3012000000.00
GSK balance_sheet (annual, 2025-12-31) — Current Liabilities: 21391000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 21391000000.00
GSK balance_sheet (annual, 2025-12-31) — Current Provisions: 938000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Current Provisions: 938000000.00
GSK cash_flow (annual, 2025-12-31) — Deferred Tax: 1112000000.00
GSK cash_flow (quarterly, 2025-12-31) — Deferred Tax: 223000000.00
GSK balance_sheet (annual, 2025-12-31) — Defined Pension Benefit: 1115000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Defined Pension Benefit: 1115000000.00
GSK cash_flow (annual, 2025-12-31) — Depreciation: 1056000000.00
GSK cash_flow (quarterly, 2025-12-31) — Depreciation: -1664000000.00
GSK cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 2314000000.00
GSK cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: -406000000.00
GSK balance_sheet (annual, 2025-12-31) — Derivative Product Liabilities: 67000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Derivative Product Liabilities: 67000000.00
GSK income_statement (annual, 2025-12-31) — Diluted Average Shares: 2058500000.00
GSK income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 2043000000.00
GSK income_statement (annual, 2025-12-31) — Diluted EPS: 2.78
GSK income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.31
GSK income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 5716000000.00
GSK income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 636000000.00
GSK cash_flow (annual, 2025-12-31) — Dividends Received Cfi: 87000000.00
GSK cash_flow (quarterly, 2025-12-31) — Dividends Received Cfi: 70000000.00
GSK income_statement (annual, 2025-12-31) — EBIT: 8088000000.00
GSK income_statement (quarterly, 2025-12-31) — EBIT: 1124000000.00
GSK income_statement (annual, 2025-12-31) — EBITDA: 10402000000.00
GSK income_statement (quarterly, 2025-12-31) — EBITDA: 1124000000.00
GSK cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -19000000.00
GSK cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -41000000.00
GSK cash_flow (annual, 2025-12-31) — End Cash Position: 3207000000.00
GSK cash_flow (quarterly, 2025-12-31) — End Cash Position: 3207000000.00
GSK balance_sheet (annual, 2025-12-31) — Financial Assets: 0.00
GSK balance_sheet (quarterly, 2025-12-31) — Financial Assets: 0.00
GSK balance_sheet (annual, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 263000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 263000000.00
GSK cash_flow (annual, 2025-12-31) — Financing Cash Flow: -3685000000.00
GSK cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -856000000.00
GSK balance_sheet (annual, 2025-12-31) — Finished Goods: 1617000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Finished Goods: 1617000000.00
GSK cash_flow (annual, 2025-12-31) — Free Cash Flow: 4756000000.00
GSK cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 1253000000.00
GSK cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -4000000.00
GSK cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of Business: 9000000.00
GSK cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: -49000000.00
GSK income_statement (annual, 2025-12-31) — General And Administrative Expense: 9088000000.00
GSK income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 2639000000.00
GSK balance_sheet (annual, 2025-12-31) — Goodwill: 7018000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Goodwill: 7018000000.00
GSK balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 23766000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 23766000000.00
GSK balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 5913000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 5913000000.00
GSK balance_sheet (annual, 2025-12-31) — Gross PPE: 20940000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Gross PPE: 20940000000.00
GSK income_statement (annual, 2025-12-31) — Gross Profit: 23650000000.00
GSK income_statement (quarterly, 2025-12-31) — Gross Profit: 5961000000.00
GSK balance_sheet (annual, 2025-12-31) — Hedging Assets Current: 121000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Hedging Assets Current: 121000000.00
GSK income_statement (annual, 2025-12-31) — Interest Expense: 687000000.00
GSK income_statement (quarterly, 2025-12-31) — Interest Expense: 174000000.00
GSK income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 687000000.00
GSK income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 174000000.00
GSK income_statement (annual, 2025-12-31) — Interest Income: 56000000.00
GSK income_statement (quarterly, 2025-12-31) — Interest Income: -74000000.00
GSK income_statement (annual, 2025-12-31) — Interest Income Non Operating: 56000000.00
GSK income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: -74000000.00
GSK cash_flow (annual, 2025-12-31) — Interest Paid Cff: -679000000.00
GSK cash_flow (quarterly, 2025-12-31) — Interest Paid Cff: -295000000.00
GSK cash_flow (annual, 2025-12-31) — Interest Received Cfi: 154000000.00
GSK cash_flow (quarterly, 2025-12-31) — Interest Received Cfi: 37000000.00
GSK balance_sheet (annual, 2025-12-31) — Inventory: 5924000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Inventory: 5924000000.00
GSK balance_sheet (annual, 2025-12-31) — Invested Capital: 33267000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Invested Capital: 33267000000.00
GSK cash_flow (annual, 2025-12-31) — Investing Cash Flow: -4233000000.00
GSK cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -933000000.00
GSK balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 1053000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 1053000000.00
GSK balance_sheet (annual, 2025-12-31) — Investmentsin Associatesat Cost: 89000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Investmentsin Associatesat Cost: 89000000.00
GSK balance_sheet (annual, 2025-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK balance_sheet (quarterly, 2025-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 15000000.00
GSK cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 1000000.00
GSK cash_flow (annual, 2025-12-31) — Issuance Of Debt: 3194000000.00
GSK cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 552000000.00
GSK balance_sheet (annual, 2025-12-31) — Land And Improvements: 6157000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 6157000000.00
GSK balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 693000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 693000000.00
GSK balance_sheet (annual, 2025-12-31) — Long Term Debt: 14015000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 14015000000.00
GSK balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14708000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14708000000.00
GSK cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 1979000000.00
GSK cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
GSK cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -1400000000.00
GSK cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: 2000000.00
GSK balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 89000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 89000000.00
GSK balance_sheet (annual, 2025-12-31) — Long Term Provisions: 610000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Long Term Provisions: 610000000.00
GSK balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 11735000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 11735000000.00
GSK balance_sheet (annual, 2025-12-31) — Minority Interest: -421000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Minority Interest: -421000000.00
GSK income_statement (annual, 2025-12-31) — Minority Interests: -573000000.00
GSK income_statement (quarterly, 2025-12-31) — Minority Interests: -91000000.00
GSK cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -1639000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -31000000.00
GSK cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -1362000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -251000000.00
GSK balance_sheet (annual, 2025-12-31) — Net Debt: 13740000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Net Debt: 13740000000.00
GSK income_statement (annual, 2025-12-31) — Net Income: 5716000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Income: 636000000.00
GSK income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 5716000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 636000000.00
GSK income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 6289000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 727000000.00
GSK income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 5716000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 636000000.00
GSK income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 5716000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 636000000.00
GSK cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 6289000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 727000000.00
GSK income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 6289000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 727000000.00
GSK cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -1522000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -449000000.00
GSK income_statement (annual, 2025-12-31) — Net Interest Income: -633000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Interest Income: -250000000.00
GSK cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 11000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 0.00
GSK cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 1506000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 548000000.00
GSK cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 579000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: 2000000.00
GSK income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -633000000.00
GSK income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -250000000.00
GSK cash_flow (annual, 2025-12-31) — Net Other Financing Charges: 46000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -25000000.00
GSK balance_sheet (annual, 2025-12-31) — Net PPE: 10048000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Net PPE: 10048000000.00
GSK cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -1324000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -560000000.00
GSK cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: 927000000.00
GSK cash_flow (quarterly, 2025-12-31) — Net Short Term Debt Issuance: 546000000.00
GSK balance_sheet (annual, 2025-12-31) — Net Tangible Assets: -7389000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -7389000000.00
GSK balance_sheet (annual, 2025-12-31) — Non Current Accrued Expenses: 6000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Non Current Accrued Expenses: 6000000.00
GSK balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 121000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 121000000.00
GSK balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 6520000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 6520000000.00
GSK balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 291000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 291000000.00
GSK balance_sheet (annual, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 1687000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 1687000000.00
GSK income_statement (annual, 2025-12-31) — Normalized EBITDA: 10707000000.00
GSK income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 1124000000.00
GSK income_statement (annual, 2025-12-31) — Normalized Income: 5975173760.30
GSK income_statement (quarterly, 2025-12-31) — Normalized Income: 636000000.00
GSK cash_flow (annual, 2025-12-31) — Operating Cash Flow: 7741000000.00
GSK cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 2278000000.00
GSK income_statement (annual, 2025-12-31) — Operating Income: 8338000000.00
GSK income_statement (quarterly, 2025-12-31) — Operating Income: 1506000000.00
GSK income_statement (annual, 2025-12-31) — Operating Revenue: 32667000000.00
GSK income_statement (quarterly, 2025-12-31) — Operating Revenue: 8618000000.00
GSK balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 4012550322.00
GSK balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 4012550322.00
GSK balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 1348000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 1348000000.00
GSK balance_sheet (annual, 2025-12-31) — Other Equity Interest: -282000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: -282000000.00
GSK balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 16748000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 16748000000.00
GSK cash_flow (annual, 2025-12-31) — Other Non Cash Items: 568000000.00
GSK cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 185000000.00
GSK balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 5385000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 5385000000.00
GSK balance_sheet (annual, 2025-12-31) — Other Payable: 438000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Payable: 438000000.00
GSK balance_sheet (annual, 2025-12-31) — Other Properties: 6000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Properties: 6000000.00
GSK balance_sheet (annual, 2025-12-31) — Other Receivables: 662000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Receivables: 662000000.00
GSK balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 9000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 9000000.00
GSK income_statement (annual, 2025-12-31) — Other Special Charges: 232000000.00
GSK income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (annual, 2025-12-31) — Payables: 4471000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Payables: 4471000000.00
GSK balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 138000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 138000000.00
GSK balance_sheet (annual, 2025-12-31) — Prepaid Assets: 385000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 385000000.00
GSK income_statement (annual, 2025-12-31) — Pretax Income: 7401000000.00
GSK income_statement (quarterly, 2025-12-31) — Pretax Income: 950000000.00
GSK balance_sheet (annual, 2025-12-31) — Properties: 0.00
GSK balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
GSK cash_flow (annual, 2025-12-31) — Purchase Of Business: -1828000000.00
GSK cash_flow (quarterly, 2025-12-31) — Purchase Of Business: -82000000.00
GSK cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -1637000000.00
GSK cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -452000000.00
GSK cash_flow (annual, 2025-12-31) — Purchase Of PPE: -1348000000.00
GSK cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -573000000.00
GSK balance_sheet (annual, 2025-12-31) — Raw Materials: 608000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Raw Materials: 608000000.00
GSK income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 9017000000.00
GSK income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2657000000.00
GSK income_statement (annual, 2025-12-31) — Reconciled Depreciation: 2314000000.00
GSK income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: -406000000.00
GSK cash_flow (annual, 2025-12-31) — Repayment Of Debt: -1688000000.00
GSK cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -4000000.00
GSK cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -1377000000.00
GSK cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -252000000.00
GSK income_statement (annual, 2025-12-31) — Research And Development: 7525000000.00
GSK income_statement (quarterly, 2025-12-31) — Research And Development: 2350000000.00
GSK balance_sheet (annual, 2025-12-31) — Restricted Cash: 247000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 247000000.00
GSK income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 581000000.00
GSK balance_sheet (annual, 2025-12-31) — Retained Earnings: 10209000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 10209000000.00
GSK cash_flow (annual, 2025-12-31) — Sale Of Business: 189000000.00
GSK cash_flow (quarterly, 2025-12-31) — Sale Of Business: 51000000.00
GSK cash_flow (annual, 2025-12-31) — Sale Of Intangibles: 115000000.00
GSK cash_flow (quarterly, 2025-12-31) — Sale Of Intangibles: 3000000.00
GSK cash_flow (annual, 2025-12-31) — Sale Of PPE: 24000000.00
GSK cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 13000000.00
GSK income_statement (annual, 2025-12-31) — Selling General And Administration: 9088000000.00
GSK income_statement (quarterly, 2025-12-31) — Selling General And Administration: 2639000000.00
GSK balance_sheet (annual, 2025-12-31) — Share Issued: 4315445026.00
GSK balance_sheet (quarterly, 2025-12-31) — Share Issued: 4315445026.00
GSK cash_flow (annual, 2025-12-31) — Short Term Debt Issuance: 1215000000.00
GSK cash_flow (quarterly, 2025-12-31) — Short Term Debt Issuance: 552000000.00
GSK cash_flow (annual, 2025-12-31) — Short Term Debt Payments: -288000000.00
GSK cash_flow (quarterly, 2025-12-31) — Short Term Debt Payments: -6000000.00
GSK income_statement (annual, 2025-12-31) — Special Income Charges: -813000000.00
GSK cash_flow (annual, 2025-12-31) — Stock Based Compensation: 374000000.00
GSK balance_sheet (annual, 2025-12-31) — Stockholders Equity: 16377000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 16377000000.00
GSK balance_sheet (annual, 2025-12-31) — Tangible Book Value: -7389000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -7389000000.00